Exposed (n=466) | Non-exposed (n=156) | RRR (95% CI)* | |
Lower respiratory tract symptoms | |||
Neither at baseline nor at follow-up | 216 (48%) | 78 (55%) | 1 (Referent) |
Only at baseline | 73 (16%) | 23 (16%) | 1.3 (0.7 to 2.2) |
Only at follow-up | 59 (13%) | 19 (13%) | 1.4 (0.7 to 2.5) |
Both at baseline and at follow-up | 102 (23%) | 22 (15%) | 2.3 (1.3 to 4.0) |
Nasal symptoms | |||
Neither at baseline nor at follow-up | 207 (45%) | 90 (58%) | 1 (Referent) |
Only at baseline | 93 (20%) | 21 (14%) | 1.9 (1.1 to 3.4) |
Only at follow-up | 72 (16%) | 28 (18%) | 1.2 (0.7 to 2.0) |
Both at baseline and at follow-up | 90 (19%) | 16 (10%) | 2.4 (1.3 to 4.5) |
Inhaled medication | |||
Neither at baseline nor at follow-up | 340 (73%) | 131 (85%) | 1 (Referent) |
Only at baseline | 30 (6%) | 3 (2%) | 3.8 (1.1 to 13) |
Only at follow-up | 57 (12%) | 16 (10%) | 1.5 (0.8 to 2.7) |
Both at baseline and at follow-up | 37 (8%) | 5 (3%) | 2.8 (1.1 to 7.5) |
Oral medication | |||
Neither at baseline nor at follow-up | 339 (73%) | 123 (80%) | 1 (Referent) |
Only at baseline | 44 (10%) | 11 (7%) | 1.4 (0.7 to 2.9) |
Only at follow-up | 46 (10%) | 15 (10%) | 1.4 (0.7 to 2.7) |
Both at baseline and at follow-up | 34 (7%) | 5 (3%) | 2.9 (1.1 to 7.7) |
For symptom definitions, see legend of table 2.
↵* RRRs and 95% CIs for exposed versus non-exposed, adjusted for sex, age, smoking status and the time elapsed between baseline and follow-up studies.
RRRs, relative risk ratios.